bs-3089R-Cy5 [Conjugated Primary Antibody]
CBL2 (Tyr731) Polyclonal Antibody, Cy5 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: CBL2 Tyr731

Modification Site: Tyr731

Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 867

Source: KLH conjugated synthetic phosphopeptide derived from human CBL2 around the phosphorylation site of Tyr731

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

The proto oncogene c CBL was initially identified as the cellular homologue of v CBL oncogene that induces pre B cell lymphomas and myeloid leukemias in mice. In more recent studies CBL has been shown to be a negative regulator of tyrosine kinase signaling. The ubiquitin ligase activity of CBL leads to the degradation of tyrosine kinases, thus attenuating the signal of receptors. Targets of CBL include activated protein tyrosine kinases belonging to the Src and Syk/Zap 70 families. An additional mechanism to attenuate receptor signaling is thought to be achieved by CBL?s interaction with downstream targets of tyrosine kinases, such as PI 3K and Vav.

Conjugation: Cy5

Excitation/ Emission: 625,650nm/670nm

Size: 100ul

Concentration: 1ug/ul

Applications: IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 100


Predicted Cross Reactive Species: Human
Mouse
Rat
Dog
Cow
Pig

For research use only. Not intended for diagnostic or therapeutic use.